About Wave Life Sciences Ltd.
https://www.wavelifesciences.comWave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression.
CEO
Paul B. Bolno
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 107
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Truist Securities
Buy
B. Riley Securities
Buy
Citigroup
Buy
Canaccord Genuity
Buy
Clear Street
Buy
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
GYON TECHNOLOGIES CAPITAL MANAGEMENT, LP
Shares:93.99M
Value:$1.36B
RA CAPITAL MANAGEMENT, L.P.
Shares:18.2M
Value:$264.11M
ADAGE CAPITAL PARTNERS GP, L.L.C.
Shares:14.57M
Value:$211.38M
Summary
Showing Top 3 of 213
About Wave Life Sciences Ltd.
https://www.wavelifesciences.comWave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $7.61M ▼ | $63.96M ▲ | $-53.85M ▼ | -707.83% ▼ | $-0.32 ▼ | $-51.62M ▼ |
| Q2-2025 | $8.7M ▼ | $59.26M ▲ | $-50.47M ▼ | -580.17% ▼ | $-0.31 ▼ | $-50.56M ▼ |
| Q1-2025 | $9.18M ▼ | $56.81M ▼ | $-46.88M ▼ | -510.93% ▼ | $-0.29 ▼ | $-47.64M ▼ |
| Q4-2024 | $83.75M ▲ | $60.78M ▲ | $29.25M ▲ | 34.93% ▼ | $0.18 ▲ | $25.12M ▲ |
| Q3-2024 | $-7.68M | $56.24M | $-61.78M | 804.85% | $-0.47 | $-61.76M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $196.22M ▼ | $241.38M ▼ | $116.83M ▲ | $124.55M ▼ |
| Q2-2025 | $208.48M ▼ | $252.35M ▼ | $113.09M ▼ | $139.27M ▼ |
| Q1-2025 | $243.07M ▼ | $288.34M ▼ | $116.54M ▼ | $171.8M ▼ |
| Q4-2024 | $302.08M ▼ | $352.21M ▼ | $142.69M ▼ | $209.51M ▲ |
| Q3-2024 | $310.95M | $358.5M | $208.99M | $149.51M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-53.85M ▼ | $-44.67M ▲ | $-248K ▲ | $32.69M ▲ | $-12.25M ▲ | $-44.91M ▲ |
| Q2-2025 | $-50.47M ▼ | $-46.01M ▲ | $-306K ▼ | $11.69M ▲ | $-34.58M ▲ | $-46.32M ▲ |
| Q1-2025 | $-46.88M ▼ | $-63.04M ▼ | $-165K ▼ | $4.16M ▼ | $-58.99M ▼ | $-63.2M ▼ |
| Q4-2024 | $29.25M ▲ | $-43.65M ▲ | $-86K ▲ | $34.98M ▼ | $-8.86M ▼ | $-43.73M ▲ |
| Q3-2024 | $-61.78M | $-46.48M | $-383K | $203.75M | $157M | $-46.86M |
CEO
Paul B. Bolno
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 107
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Truist Securities
Buy
B. Riley Securities
Buy
Citigroup
Buy
Canaccord Genuity
Buy
Clear Street
Buy
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
GYON TECHNOLOGIES CAPITAL MANAGEMENT, LP
Shares:93.99M
Value:$1.36B
RA CAPITAL MANAGEMENT, L.P.
Shares:18.2M
Value:$264.11M
ADAGE CAPITAL PARTNERS GP, L.L.C.
Shares:14.57M
Value:$211.38M
Summary
Showing Top 3 of 213